(firstQuint)Pilot Assessment of Lopinavir/Ritonavir and Maraviroc.

 As long-term toxicity to many of the nucleoside medications have become known, interest has increased in treatment regimens that do not use these medications.

 This study is to assess the response of one such "nucleoside-sparing" therapy in patients who are showing failure to their initial nucleoside-containing treatment regimen.

.

 Pilot Assessment of Lopinavir/Ritonavir and Maraviroc@highlight

This is a study to assess the response of lopinavir/ritonavir plus maraviroc (with no nucleoside medications) in HIV patients failing their initial antiviral therapy.

